Afficher la notice abrégée

dc.creatorKyrgias, G.en
dc.creatorTheodorou, K.en
dc.creatorZygogianni, A.en
dc.creatorTsanadis, K.en
dc.creatorZervoudis, S.en
dc.creatorTzitzikas, J.en
dc.creatorKoukourakis, M.en
dc.date.accessioned2015-11-23T10:37:13Z
dc.date.available2015-11-23T10:37:13Z
dc.date.issued2012
dc.identifier.issn11791314
dc.identifier.urihttp://hdl.handle.net/11615/30090
dc.description.abstractPurpose: Connective vascular diseases (CVD), including scleroderma, are reported to represent for some researchers a relative contraindication and for others absolute contraindication for radiotherapy. The purpose of our study is to add four new cases to the existing body of international literature and to determine whether women with pre-existing scleroderma who have been surgically treated for early breast cancer could undergo postsurgical radiotherapy without serious early and late complications. Patients and methods: From May 1998 to November 2010, we irradiated for early breast cancer four patients suffering from pre-existing scleroderma; after conservative surgery, we performed whole breast postoperative radiotherapy of 50.4 Gy total dose to the whole breast plus a 9 Gy boost to the tumor bed. We reviewed the records of all four patients and evaluated the early and late reactions using acute radiation morbidity scoring criteria (Radiation Therapy Oncology Group [RTOG], American College of Radiology, Philadelphia, PA) and late radiation morbidity scoring scheme (European Organisation for Research and Treatment of Cancer [EORTC], Brussels, Belgium and RTOG). Results: After a median follow-up of 105 months (range 12-155 months) the early and late toxicity concerning the skin, the subcutaneous tissues, the lungs, and the heart have been acceptable and are in full accordance with what have been reported in international literature. Conclusion: This study matches global experience, which shows that patients with scleroderma and breast cancer must be discussed by the multidisciplinary tumor board in order for a personalized treatment strategy to be formulated. Radiation therapy can be proposed as a postsurgical therapeutic option in selected cases. © 2012 Kyrgias et al, publisher and licensee Dove Medical Press Ltd.en
dc.source.urihttp://www.scopus.com/inward/record.url?eid=2-s2.0-84862510456&partnerID=40&md5=6731f9dc9ae57eb2639fd318f3451512
dc.subjectBreast radiotherapyen
dc.subjectEarly toxicityen
dc.subjectLate complicationsen
dc.subjectSclerodermaen
dc.subjectShort reviewen
dc.subjectcyclophosphamideen
dc.subjectdocetaxelen
dc.subjectdoxorubicinen
dc.subjectepirubicinen
dc.subjectfluorouracilen
dc.subjectmethotrexateen
dc.subjectarticleen
dc.subjectbreast canceren
dc.subjectcancer combination chemotherapyen
dc.subjectcancer radiotherapyen
dc.subjectfollow upen
dc.subjecthumanen
dc.subjectmorbidityen
dc.subjectradiation doseen
dc.subjectscoring systemen
dc.titleRadiotherapy of early breast cancer in scleroderma patients: Our experience with four cases and a short review of the literatureen
dc.typejournalArticleen


Fichier(s) constituant ce document

FichiersTailleFormatVue

Il n'y a pas de fichiers associés à ce document.

Ce document figure dans la(les) collection(s) suivante(s)

Afficher la notice abrégée